Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
Mediators Inflamm ; 2022: 5665778, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-35915741

RESUMEN

Inflammatory bowel disease (IBD) is a chronic autoimmune disorder stemming from unrestrained immune activation and subsequent destruction of colon tissue. Genetic susceptibility, microbiota remodeling, and environmental cues are involved in IBD pathogenesis. Up to now, there are limited treatment options for IBD, so better therapies for IBD are eagerly needed. The therapeutic effects of naturally occurring compounds have been extensively investigated, among which quercetin becomes an attractive candidate owing to its unique biochemical properties. To facilitate the clinical translation of quercetin, we aimed to get a comprehensive understanding of the cellular and molecular mechanisms underlying the anti-IBD role of quercetin. We summarized that quercetin exerts the anti-IBD effect through consolidating the intestinal mucosal barrier, enhancing the diversity of colonic microbiota, restoring local immune homeostasis, and restraining the oxidative stress response. We also delineated the effect of quercetin on gut microbiome and discussed the potential side effects of quercetin administration. Besides, quercetin could serve as a prodrug, and the bioavailability of quercetin is improved through chemical modifications or the utilization of effective drug delivery systems. Altogether, these lines of evidence hint the feasibility of quercetin as a candidate compound for IBD treatment.


Asunto(s)
Microbioma Gastrointestinal , Enfermedades Inflamatorias del Intestino , Colon/patología , Humanos , Enfermedades Inflamatorias del Intestino/tratamiento farmacológico , Mucosa Intestinal , Quercetina/uso terapéutico
2.
Pak J Pharm Sci ; 32(1(Special)): 421-426, 2019 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-30852479

RESUMEN

At present, the main methods of clinical treatment of ovarian cancer are cytoreductive surgery and multidrug combination chemotherapy, in which multidrug combination chemotherapy is based on platinum drugs. Mifepristone can be used as an adjuvant drug for the treatment of drug-resistant and refractory ovarian cancer because of its convenient oral administration, long half-life, low cytotoxicity to normal cells, anti-tumor activity and chemosensitizing effect. This article analyzed the clinical effect of mifepristone combined with bevacizumab in the treatment of patients with ovarian cancer. Sixty patients were randomly divided into experimental group and control group. Mifepristone combined with bevacizumab was used in experimental group and conventional anticancer drugs were used in control group. The results showed that the amount of bleeding during labor (6.38±1.85 mL), the rate of birth injury (0%) and the amount of bleeding 2 hours after delivery (63.12±19.86 mL) in the experimental group were significantly better than those in the control group (P<0.05), and the incidence of side effects and complications were significantly lower than those in the control group (P<0.05). In conclusion, mifepristone combined with bevacizumab in the treatment of high-risk pregnancy complicated with ovarian cancer can significantly reduce the patient's labor process and the amount of bleeding at different stages after surgery, the incidence of side effects and complications after surgery is significantly reduced, which is conducive to the recovery of the patient's body. .


Asunto(s)
Adenocarcinoma/tratamiento farmacológico , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Bevacizumab/uso terapéutico , Mifepristona/uso terapéutico , Neoplasias Ováricas/tratamiento farmacológico , Complicaciones Neoplásicas del Embarazo/tratamiento farmacológico , Adenocarcinoma/patología , Adulto , Protocolos de Quimioterapia Combinada Antineoplásica/administración & dosificación , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Bevacizumab/administración & dosificación , Bevacizumab/efectos adversos , Quimioterapia Adyuvante , Femenino , Humanos , Mifepristona/administración & dosificación , Mifepristona/efectos adversos , Estadificación de Neoplasias , Neoplasias Ováricas/patología , Embarazo , Complicaciones Neoplásicas del Embarazo/patología , Resultado del Embarazo , Embarazo de Alto Riesgo
3.
Int Health ; 15(4): 397-402, 2023 07 04.
Artículo en Inglés | MEDLINE | ID: mdl-36071547

RESUMEN

BACKGROUND: During the coronavirus disease 2019 pandemic, a nucleic acid test is frequently conducted to identify positive cases. Compared with a hospital-based strategy, whole-community nucleic acid testing displays a unique advantage in rapid screening of a massive population. Yet a management plan to ensure ample and contamination-free sample collection is lacking.The objective of the current study was to establish an efficient operational mode of whole-community nucleic acid testing by management of a sample collection team and to provide a reference for joint prevention work to contain the spread of severe acute respiratory syndrome coronavirus 2. METHODS: The efficient operation of nucleic acid testing within the community was implemented by urgent setting up of sample collection teams, efficient allocation of medical supplies, optimization of management procedures and coordination among multiple working departments. RESULTS: A total of 21 585 nucleic acid samples were collected within 3 d, while no one was missed or experienced a cross infection. No falls, heatstroke, disputes or other adverse events occurred. CONCLUSIONS: Under the emergency setting of nucleic acid testing of a large population, a management system with orderly organization, clear division of responsibilities and standardized operational procedures should be formulated.


Asunto(s)
COVID-19 , Ácidos Nucleicos , Humanos , SARS-CoV-2 , COVID-19/diagnóstico , Pandemias
4.
Front Public Health ; 11: 1103325, 2023.
Artículo en Inglés | MEDLINE | ID: mdl-37006565

RESUMEN

Introduction: Nurses have a high prevalence of occupational low back pain, especially since the outbreak of the COVID-19 pandemic, which has increased the nurses' workloads. It has brought a huge burden on nurses and their professional development. Nurses' occupational low back pain prevention capacity is the logical starting point and core of interventions to prevent its occurrence. To date, there is no study investigating it with a scientific scale. Therefore, a multicenter cross-sectional study was conducted to explore the current status of nurses' capacity in occupational low back pain prevention and its influencing factors in China. Methods: Using a two-stage, purposive and convenience mixed sampling method, 1331 nurses from 8 hospitals across 5 provinces (Hubei, Zhejiang, Shandong, Henan, and Sichuan) in the southern, western, northern, and central areas of mainland China were involved in this study. The demographic questionnaire and occupational low back pain prevention behavior questionnaire were used for data collection. The descriptive analysis, univariate analysis, and multiple stepwise linear regression were used for data analysis. Results: The results showed that the occupational low back pain prevention behavior questionnaire score was 89.00 (80.00, 103.00) [M (Q1, Q3)], which indicated that nurses' ability was at a moderate level. Participation in prevention training before, perceived stress at work, and working hours per week were predictors for nurses' occupational low back pain prevention capacity. Discussion: To improve nurses' prevention ability, nursing managers should organize various training programs, strengthen regulations to reduce nurses' workload and stress, provide a healthy workplace, and offer incentives to motivate nurses.


Asunto(s)
COVID-19 , Dolor de la Región Lumbar , Humanos , Estudios Transversales , Dolor de la Región Lumbar/prevención & control , Dolor de la Región Lumbar/epidemiología , Pandemias , COVID-19/epidemiología , Hospitales
5.
Transl Cancer Res ; 12(3): 595-604, 2023 Mar 31.
Artículo en Inglés | MEDLINE | ID: mdl-37033361

RESUMEN

Background: Endometrial carcinoma (EC) is one of the most common gynecological malignancies and has become more prevalent in recent decades. The clinical manifestations and characteristics of EC in premenopausal and postmenopausal women differ and present with distinct pathological stages and subtypes of EC. Surgery remains the principal therapeutic approach, but the postoperative prognosis is largely affected by the pathological state. Methods: A retrospective study was conducted on 216 patients with EC who were hospitalized from August 2008 to August 2019 in Wuhan Union Hospital. The patients were divided into 2 groups based on the pre- or postmenopausal occurrence of EC. The general clinical characteristics, intraoperative situation, clinicopathological data, and postoperative outcomes of the 2 groups were compared. Results: Patients with premenopausal EC had earlier menarche, a higher incidence of primary infertility and anemia, and fewer pregnancies and deliveries. Patients with postmenopausal EC were older and often had hyperlipidemia and diabetes. Additionally, patients who were postmenopausal had worse tumor pathological gradings, more severe muscular invasion, and a higher rate of lymphatic metastasis. These factors led to a higher demand for postoperative radiotherapy in patients but a lower survival rate. Conclusions: Generally, premenopausal EC differs from postmenopausal EC: the latter is more malignant and has a worse prognosis.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA